(Total Views: 831)
Posted On: 02/11/2025 5:57:14 PM
Post# of 155802
Are we over complicating?
GSK/Pfizer buys a basket of indications.
$400m each up front.
5 year royalties.
A mfgr facility.
BG/ViiV buys Hiv.
Madgril buys MASH.
Upfront cash from both.
5 yr royalties from both.
Cytodyn could have billions in the bank overnight.
Say there are 9/10 (+/-) other companies also interested in Leronlimab.
Each interested in 3-4 indications.
$500m upfront each indication.
5 year royalties each indication.
All companies pay a Mfgr Tolling Fee of cost + 10%, to GSK/Pfizer.
No company ever needs to raise massive amounts of funding.
Cytodyn retains current & future patents.
Later dividends on current share holdings.
Sound crazy ?
It's the same lucrative model GSK/Pfizer would do.
So why not us ?
GSK/Pfizer buys a basket of indications.
$400m each up front.
5 year royalties.
A mfgr facility.
BG/ViiV buys Hiv.
Madgril buys MASH.
Upfront cash from both.
5 yr royalties from both.
Cytodyn could have billions in the bank overnight.
Say there are 9/10 (+/-) other companies also interested in Leronlimab.
Each interested in 3-4 indications.
$500m upfront each indication.
5 year royalties each indication.
All companies pay a Mfgr Tolling Fee of cost + 10%, to GSK/Pfizer.
No company ever needs to raise massive amounts of funding.
Cytodyn retains current & future patents.
Later dividends on current share holdings.
Sound crazy ?
It's the same lucrative model GSK/Pfizer would do.
So why not us ?
(7)
(0)
